Symbol Therapeutics
Modified Protein for Treatment of Autoimmune Diseases
Company Overview
Snapshot
Founded in November 2021, Symbol Therapeutics operates with 1–10 employees. The company has raised $3 million across one funding round from two investors, including RMGP Biopharma Investment Fund. Symbol Therapeutics ceased operations in November 2025.
Business overview
Symbol Therapeutics is a drug discovery company focused on developing a novel immunoregulatory therapeutic protein. Its core technology involves a modified form of the endogenous Semaphorin3A, designed to activate anti-inflammatory regulatory mechanisms and restore normal immune homeostasis. The company targets the treatment of systemic lupus erythematosus and other autoimmune diseases, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Company Intelligence Q&A
- What is Symbol Therapeutics' primary focus?
- Symbol Therapeutics is a drug discovery company developing a novel immunoregulatory therapeutic protein for the treatment of systemic lupus erythematosus and other autoimmune diseases.
- When was Symbol Therapeutics founded?
- Symbol Therapeutics was founded in November 2021.
- What is the status of Symbol Therapeutics?
- Symbol Therapeutics is non-active and ceased to operate in November 2025.
- What is Symbol Therapeutics' core technology?
- Symbol Therapeutics' proprietary technology involves a modified form of the endogenous Semaphorin3A, designed to activate anti-inflammatory regulatory mechanisms.
- Which investors participated in Symbol Therapeutics' funding round?
- In September 2022, Symbol Therapeutics received funding from RMGP Biopharma Investment Fund and FutuRx.